Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

No FDA-approved rapid tests exist that specifically test for H5N1, and the first near-point-of-care test for mpox was ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...

FDA reccommends checking the shelf life of COVID anitigen test close to expiring due to some test with different dates from ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... are hoping the same rapid development and deployment ...

BioNTech already owned part of InstaDeep as it backed the company's $100 million Series B last year, but will take 100% control of the company if the merger goes ahead as planned.

The growing prevalence of cardiovascular and thrombotic disorders is driving strong demand for D-dimer testing. As blood clot-related risk factors continue to increase, the need for precise ...

EHang Holdings Limited ("EHang" or the "Company") (Nasdaq: EH), the world's leading Urban Air Mobility ("UAM") technology ...

Highly accurate (both sensitive and specific), cheap and simple rapid diagnostic tests (RDTs) are therefore crucial for case-management of VL. Early case detection followed by adequate treatment ...